Developments in the armamentarium for the management of patients with breast cancer mean that today, it is essential in clinical practice to be able to discriminate precisely among HER2-positive, HER2-low, and HER2 IHC 0 tumours. This evidence concerns the gene ERBB2 and breast cancer.